PACIRA PHARMACEUTICALS INC 2024-07-03 Health serious FDA
Health · FDA · Recall #FDA-D-0567-2024
Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per… Recall
Issued July 3, 2024 · PACIRA PHARMACEUTICALS INC
In July 2024, PACIRA PHARMACEUTICALS INC recalled the Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C
What you should do
- 1 Stop using Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact PACIRA PHARMACEUTICALS INC to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- PACIRA PHARMACEUTICALS INC
- Category
- Health
- Recall date
- July 3, 2024
- Units affected
- Not reported
- Sold at
- US Nationwide.
- Recall number
- FDA-D-0567-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- PACIRA PHARMACEUTICALS INC has 1 recall in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.